




Contents lists available at ScienceDirect

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard



Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study



Giacomo Zoppellaro ^{a,1}, Luca Zanella ^{a,1}, Gentian Denas ^{a,1}, Nicola Gennaro ^{b,1}, Eliana Ferroni ^{b,1}, Ugo Fedeli ^{b,1}, Seena Padayattil Jose ^{a,1}, Giorgio Costa ^{c,1}, Maria Chiara Corti ^{b,1}, Margherita Andretta ^{c,1}, Vittorio Pengo ^{a,*,1}

^a Cardiology Clinic, Department of Cardiac, Thoracic and Vascular Sciences, Padua University Hospital, Padua, Italy

^b Epidemiological Department (SER), Veneto Region, Padua, Italy

^c Unified Pharmaceutical Coordination Centre (CRUF), Veneto Region, Venice, Italy

Background

- NOACs have shown non-inferiority to warfarin for the prevention of stroke and systemic embolism, with marked reduction in the risk of intracerebral haemorrhage
- Although elderly patients (≥ 75 years of age) are well represented in phase III clinical trials (30–40%), less is known of very elderly patients aged ≥ 80 years
- Aim of the present study was to evaluate the efficacy and safety of NOACs in comparison to well-managed VKAs in very elderly patients with NVAf living in an area well covered by anticoagulation clinics (Veneto Region).

Methods (1)

- Retrospective cohort study
- Two cohorts of patients: one assuming NOACs (rivaroxaban, dabigatran or apixaban), one assuming VKAs
- Demographics, comorbidities, concomitant therapies were recorded
- CHA₂DS₂VASc score and HAS-BLED score were calculated

Methods (2)

- Study endpoints were: ischaemic stroke, major bleeding, myocardial infarction and death from any cause.
- Major bleeding events were further classified as gastrointestinal (GI) bleeding (upper tract, lower tract or unspecified site of bleeding), genitourinary haemorrhage, intracranial haemorrhage (ICH) or bleeding from other sources

Results (1)

- 15,136 patients (≥ 80 y) with NVAF (2882 assuming NOACs and 12,254 assuming VKAs). The distribution of patients receiving specific NOAC agents was 30%, 42% and 28% for dabigatran, rivaroxaban and apixaban, respectively.
- Significantly higher CHA₂DS₂-VASc and HASBED score in NOACs group (4.33 ± 1.31 vs. 4.06 ± 1.19 and 2.72 ± 0.90 vs. 2.54 ± 0.85 for NOACs versus VKAs, respectively).
- VKA patients showed higher prevalence of congestive heart failure or left ventricular dysfunction and abnormal renal function.
- Median follow-up was 14.7 months (IQR: 8.1–22.8).

Table 1

Baseline demographics and clinical characteristics of study subjects treated with NOAC or VKA before application of propensity score.

	NOACs (n = 2882)	VKAs (n = 12,254)	p-Value
Age class			
80–84 years	48,8%	55,1%	p < 0,001
≥ 85 years	51,2%	44,9%	
Gender			
Male	37,4%	40,9%	p < 0,001
Female	62,6%	59,1%	
Comorbidities			
Congestive heart failure	15,0%	17,0%	p = 0,009
Hypertension	81,0%	80,7%	p = 0,721
Ictus/TIA/Thromboembolism	26,7%	13,3%	p < 0,001
Myocardial Infarction	2,7%	2,9%	p = 0,619
Peripheral artery disease	1,8%	2,2%	p = 0,175
Diabetes	17,2%	18,3%	p = 0,170
Cancer	9,8%	9,7%	p = 0,835
Chronic renal disease	4,0%	6,2%	p < 0,001
Chronic liver disease	1,1%	0,9%	p = 0,285
History of bleeding	4,2%	2,7%	p < 0,001
Risk scores at baseline			
CHA ₂ DS ₂ VASc, mean ± SD	4,33 ± 1,31	4,06 ± 1,19	p < 0,001
2–3	27,8%	32,9%	p < 0,001
4–5	51,1%	55,1%	
≥6	21,0%	12,0%	
HASBED, mean ± SD	2,72 ± 0,90	2,54 ± 0,85	p < 0,001
Modifiable risk factors			
Hypertension	81,0%	80,7%	p = 0,721
Previous use of aspirin or clopidogrel	49,9%	41,0%	
Concomitant use of NSAID	17,5%	19,4%	p = 0,02

TIA: transient ischemic attack; VKA: vitamin K antagonist; NOAC: non-VKA oral anticoagulants; NSAID: Non-steroidal inflammatory drugs.

Results (2)

- The HR for stroke and major bleeding did not significantly differ among groups (HR 0.98; 95% CI 0.65–1.49 and HR 1.05; 95% CI 0.80–1.37, respectively).
- The risk of ICH was lower with NOACs than VKAs, although not reaching statistical significance (HR 0.66; 95% CI 0.40–1.07).
- The risk of GI bleeding was significantly higher with NOACs as compared with VKAs (HR of 1.73, 95% CI 1.17–2.56). This difference was mainly due to lower tract GI bleeding (HR 2.52, 95% CI 1.28–4.95).
- The risk of death was significantly lower in the NOACs cohort as compared to VKAs (HR of 0.87, 95% CI 0.77–0.99).




Fig. 2. Study endpoints in the *intention to treat* analysis.

Discussion

- Main result of this study is that NOACs maintained an equivalent effectiveness and safety (with a reduction in mortality rate) and a different pattern of bleeding complications compared to well-managed VKAs
- Compared to VKAs, very elderly patients treated with NOACs displayed a lower risk of intracranial bleeding and a higher risk of GI haemorrhage, especially in the lower tract
- The proposed mechanism to NOACs-related GI bleeding is the increased topical anticoagulant effect due to high concentration of active agent in the GI lumen

Conclusions

- In comparison to well-managed VKA therapy, NOACs in very elderly patients with NVAF reduce intracerebral haemorrhage and increase GI bleeding, mostly from the lower tract.
- Very elderly patients at high risk of GI bleeding (previous GI bleeding, peptic ulcer, diverticulitis, intestinal angiodysplasia, polyps, etc.) should be carefully monitored while on anticoagulation with NOACs.